Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Secondary Prophylaxis with Reduced Dose Apixaban in the Morbidly Obese

Noelle W Townsend, Eliot A Rapoport, Nadine Farhat, Parth Patel, Gretchen H Mackie, Swapna Keshamoni, Henny H Billett

Blood (2024) 144 (Supplement 1): 2631.

https://doi.org/10.1182/blood-2024-201766

Published: 2024

Journal Articles

Impact of Patient and Donor Factors on Successful Hematopoietic Stem Cell Transplantation for Acute T-Cell Leukemia/Lymphoma Patients in an Underserved Minority Population

Blood (2024) 144 (Supplement 1): 4443.

https://doi.org/10.1182/blood-2024-211956

Published: 2024

Journal Articles

An Analysis of e-Iron: Updates from a Year of Experience with a Novel IV Iron Telemedicine Platform

Eliot A. Rapoport, Mark Chaitowitz

Blood (2022) 140 (Supplement 1): 5023–5024.

https://doi.org/10.1182/blood-2022-170741

Published: 2022

Journal Articles

Phase I Trial of Bortezomib (V) in Combination with “DT-PACE”: Toxicity, Stem Cell Collection and Engraftment in Newly Diagnosed Multiple Myeloma (MM) Patients (Pts).

Ashraf Badros, A. Rapoport, O. Goloubeva, K. Ruehle, S. Westphal, S. Hefner, B. Meisenberg

Blood (2005) 106 (11): 2747.

https://doi.org/10.1182/blood.V106.11.2747.2747

Published: 2005

Journal Articles

Monoclonal antibody 7G3 recognizes the N-terminal domain of the human interleukin-3 (IL-3) receptor alpha-chain and functions as a specific IL-3 receptor antagonist

Q Sun, JM Woodcock, A Rapoport, FC Stomski, EI Korpelainen, CJ Bagley, GJ Goodall, WB Smith, JR Gamble, MA Vadas, AF Lopez

Blood (1996) 87 (1): 83–92.

https://doi.org/10.1182/blood.V87.1.83.83

Published: 1996

NARROW

Secondary Prophylaxis with Reduced Dose Apixaban in the Morbidly Obese

Impact of Patient and Donor Factors on Successful Hematopoietic Stem Cell Transplantation for Acute T-Cell Leukemia/Lymphoma Patients in an Underserved Minority Population

An Analysis of e-Iron: Updates from a Year of Experience with a Novel IV Iron Telemedicine Platform

Phase I Trial of Bortezomib (V) in Combination with “DT-PACE”: Toxicity, Stem Cell Collection and Engraftment in Newly Diagnosed Multiple Myeloma (MM) Patients (Pts).

Monoclonal antibody 7G3 recognizes the N-terminal domain of the human interleukin-3 (IL-3) receptor alpha-chain and functions as a specific IL-3 receptor antagonist

Email alerts

ASH Publications

American Society of Hematology

Secondary Prophylaxis with Reduced Dose Apixaban in the Morbidly Obese

Impact of Patient and Donor Factors on Successful Hematopoietic Stem Cell Transplantation for Acute T-Cell Leukemia/Lymphoma Patients in an Underserved Minority Population

An Analysis of e-Iron: Updates from a Year of Experience with a Novel IV Iron Telemedicine Platform

Phase I Trial of Bortezomib (V) in Combination with “DT-PACE”: Toxicity, Stem Cell Collection and Engraftment in Newly Diagnosed Multiple Myeloma (MM) Patients (Pts).

Monoclonal antibody 7G3 recognizes the N-terminal domain of the human interleukin-3 (IL-3) receptor alpha-chain and functions as a specific IL-3 receptor antagonist

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only